Foley Hoag LLP advised biotechnology company Morphic Therapeutic in its $80 million Series B financing to fund its two lead programs through clinical proof of concept, and to advance other programs into the clinic. The financing was led by Omega Funds and Novo Holdings, with participation from new investors, including Invus and EcoR1 Capital as well as Morphic’s Series A investors.
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on integrin biology breakthroughs from the lab of noted entrepreneur and scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc. that facilitates the rapid and iterative design of clinical candidates.
Foley Hoag attorneys Mark Haddad, Patrick Connolly and Jason Roche advised Morphic in the transaction.